Bristol Myers, Cellares sign global CAR-T deal as biopharma companies look to diversify manufacturing partners 

Cel­lares has inked its first in­ter­na­tion­al deal with Bris­tol My­ers Squibb, with the cell ther­a­py man­u­fac­tur­er not­ing it is go­ing through “tremen­dous tail­winds” from the Biose­cure Act with in­creased in­ter­est from many po­ten­tial clients.

Bris­tol My­ers has re­served clin­i­cal and com­mer­cial ca­pac­i­ty for an undis­closed num­ber of CAR-T ther­a­pies at Cel­lares’ fu­ture fa­cil­i­ties in the US, EU and Japan, which are slat­ed to open in the next few years. “We’re build­ing out un­prece­dent­ed amounts of cell ther­a­py ca­pac­i­ty,” CEO Fabi­an Ger­ling­haus told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.